The red-hot field of RNA interference (RNAi) could benefit from patents issued jointly to Queensland, Australia-based Benitec, and the State of Queensland (US patent 6,573,099, issued June 3, 2003, ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

Coronavirus disease 2019 (COVID-19) vaccines have played a critical role in reducing transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. However, with ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Getting siRNA into the Right Place in the Cell Might Not Be a Problem for Much Longer For about five years now, pharmaceutical companies have been interested in developing therapeutics based on the ...

− Agreement Combines PeptiDream’s Peptide Discovery Platform to Identify High Affinity Peptide Ligands with Alnylam’s Expertise in siRNA-Conjugate-Based Delivery and in Developing and Commercializing ...

Researchers Tout Delivery Strategies that Have the Potential to Get New Drugs into Trials Sooner As more of the human genome is identified and characterized, new frontiers open for therapeutics. “The ...

In drug discovery, very little of what’s learned from one project can typically be carried over to the next. “For every new target you go after with a small molecule, you basically start from scratch, ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

A research group led by Prof. GUANG Shouhong from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, collaborating with Prof. FENG Xuezhu from the First ...

CAMBRIDGE, Mass. — Researchers at MIT and Alnylam Pharmaceuticals report this week that they have successfully used RNA interference to turn off multiple genes in the livers of mice, an advance that ...